- Home
- Publications
- Publication Search
- Publication Details
Title
Large granular lymphocytosis during dasatinib therapy
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 15, Issue 3, Pages 247-255
Publisher
Informa UK Limited
Online
2013-12-18
DOI
10.4161/cbt.27310
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients
- (2013) A. Jerez et al. BLOOD
- Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood
- (2012) J. Tanaka et al. BLOOD
- STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia
- (2012) A. Jerez et al. BLOOD
- The Transcription Factors T-bet and Eomes Control Key Checkpoints of Natural Killer Cell Maturation
- (2012) Scott M. Gordon et al. IMMUNITY
- Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib
- (2012) Nicole Hassold et al. INTERNATIONAL JOURNAL OF CANCER
- Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients
- (2012) Hideo Tanaka et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
- (2012) S Mustjoki et al. LEUKEMIA
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia
- (2011) Su Jin Lee et al. AMERICAN JOURNAL OF HEMATOLOGY
- Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
- (2011) J. C. Montero et al. CLINICAL CANCER RESEARCH
- Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
- (2011) A Kreutzman et al. LEUKEMIA
- A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors
- (2011) John J. Powers et al. LEUKEMIA & LYMPHOMA
- Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
- (2010) A. Kreutzman et al. BLOOD
- Transcriptional regulation of natural killer cell development
- (2010) Kevin Ramirez et al. CURRENT OPINION IN IMMUNOLOGY
- Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
- (2010) Peter Rohon et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
- (2010) Yasunobu Nagata et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling
- (2010) J. Chen et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib
- (2010) Jason N. Valent et al. LEUKEMIA RESEARCH
- Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches
- (2009) R. Zambello et al. HAEMATOLOGICA
- Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro
- (2009) Stephen J. Blake et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
- (2009) S Mustjoki et al. LEUKEMIA
- A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia
- (2008) X. Chen et al. BLOOD
- Dasatinib suppresses in vitro natural killer cell cytotoxicity
- (2008) S. J. Blake et al. BLOOD
- Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis
- (2008) Hugues de Lavallade et al. BRITISH JOURNAL OF HAEMATOLOGY
- Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib
- (2008) R. Weichsel et al. CLINICAL CANCER RESEARCH
- The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
- (2008) Stephen Blake et al. CLINICAL IMMUNOLOGY
- Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens
- (2008) Fei Fei et al. EXPERIMENTAL HEMATOLOGY
- Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
- (2008) Cara K. Fraser et al. EXPERIMENTAL HEMATOLOGY
- Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
- (2008) D. H. Kim et al. HAEMATOLOGICA
- Network model of survival signaling in large granular lymphocyte leukemia
- (2008) R. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now